
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
Intranasal Therapeutics, Inc. (ITI, Montvale, NJ, www.intranasal.com), has appointed Peter F. Young as president and chief executive officer.
Intranasal Therapeutics, Inc. (ITI, Montvale, NJ,







